AERIE PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
AERIE PHARMACEUTICALS INC. - More news...
AERIE PHARMACEUTICALS INC. - More news...
- Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
- AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
- AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
- Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
- AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
- AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
- SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
- Thinking about buying stock in FuboTV, Aerie Pharmaceuticals, Waitr, Tilray, or AMC Entertainment?
- Shareholder Alert: Ademi LLP investigates whether Aerie Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alcon
- Aerie Pharmaceuticals Announces New Employee Inducement Grant
- Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
- Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
- Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
- Aerie Pharmaceuticals Announces New Employee Inducement Grant
- Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
- Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
- Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
- Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
- Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
- Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
- Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
- Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
- Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
- Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
- Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
- Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
- Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update